Skip to main content

For the first time, Sun Pharma outperforms Mankind in prescription


Clinical courses


Clinical research courses

Sun Pharma outperforms Mankind in prescription

For the first time Sun Pharma secured the top position by doctor prescriptions. It outperforms Mankind Pharma long stand, according to market research firm, SMSRC.

Sun Pharma is the largest Indian pharma company by capital, but Mankind Pharma was leading market rank for number of doctor prescriptions for a long time. Recently as per market research firm, SMSRC, Sun Pharma, which has topped India’s pharma retail market for years, has now become the leader in prescriptions, bolstered by an increase in field force and a sharper focus on core therapies.

As per SMSRC MAT August-2022 report, Sun Pharma is No.1 ranked by prescription share. Though Sun Pharma being a specialty company with limited coverage with GPs, we have become No. 1 in terms of prescription share. In addition, it has a leadership position across 12 doctor specialties, said Kirti Ganorkar, CEO of the company.

He further said, We continue to outperform the average industry growth, which has led to increase in our overall market share. As per AIOCD AWACS Sept-2022 MAT data, we are ranked No.1 in India and our market share has improved by about 0.5 pc over the last one year, to approximately 8.6 pc.

Sun Pharma has shown strong consolidated sales for the quarter of Rs.108,092 million, up 13.1 pc YoY. Most of the businesses witnessed good growth led by the global specialty business, India and Emerging Markets. For Q2, our global specialty revenue was up 27.5 pc YoY to about USD 201 million. Ilumya, Cequa and Winlevi were the growth drivers for the quarter.